New vaccine aims to stop inherited cancer before it starts
NCT ID NCT05078866
Summary
This trial is testing a vaccine called Nous-209 in people with Lynch syndrome, a genetic condition that greatly increases the risk of colorectal and other cancers. The vaccine is designed to teach the body's immune system to recognize and attack early cancer cells. Researchers want to see if the vaccine is safe and if it can trigger an immune response that might prevent tumors from forming.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYNCH SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Puerto Rico
San Juan, 00936, Puerto Rico
Conditions
Explore the condition pages connected to this study.